Chronic lung diseases : pathophysiology and therapeutics /: pathophysiology and therapeutics. (2020)

• Record Type: Book
• Further Information: Note: Sheikh Rayees, Inshah Din, Gurdarshan Singh, Fayaz A. Malik, editors.
• Other Names: Rayees, Sheikh; Din, Inshah; Singh, G. D (Gur Darshan), 1962-; Malik, Fayaz A
• Contents: Intro -- Contents -- About the Editors -- 1: Therapeutic Advances in the Management of Pulmonary Arterial Hypertension -- 1.1 Introduction -- 1.2 Basic Review of Pulmonary Circulation -- 1.3 Pulmonary Hypertension: Clinical Classification -- 1.3.1 Group 1: Pulmonary Arterial Hypertension (PAH) -- 1.3.2 Group 2: Pulmonary Hypertension (PH) Due to Left Heart Disease -- 1.3.3 Group 3: Pulmonary Hypertension (PH) Due to Lung Diseases and Hypoxia -- 1.3.4 Group 4: Chronic Thromboembolic PH (CTEPH) -- 1.3.5 Group 5: PH with Unclear Multifactorial Mechanism 1.4 Mechanisms of Pathogenesis and Pathophysiology of Pulmonary Hypertension -- 1.4.1 Prostacyclin and Thromboxane A2 -- 1.4.2 Endothelin-1 -- 1.4.3 Nitric Oxide -- 1.4.4 Serotonin -- 1.4.5 Vasoactive Intestinal Peptide -- 1.4.6 Vascular Endothelial Growth Factors -- 1.5 Emerging Therapeutics in the Management of Pulmonary Arterial Hypertension -- 1.5.1 Sex Hormones -- 1.5.2 Genes, Epigenetics, and MicroRNAs -- 1.5.3 Elastase Inhibition -- 1.5.4 Inflammation and Immunity -- 1.5.5 Mitochondrial Dysfunction -- 1.5.6 Other Metabolic Pathways -- 1.5.7 Nervous System 1.5.8 Renin-Angiotensin-Aldosterone System (RAAS) -- 1.6 Summary -- References -- 2: Asthma: Pathophysiology, Current Status, and Therapeutics -- 2.1 Introduction -- 2.1.1 Childhood Asthma -- 2.1.2 Adult-Onset Asthma -- 2.1.3 Occupational Asthma -- 2.1.4 Difficult-to-Control and Severe Asthma -- 2.1.5 Seasonal Asthma -- 2.2 Causes -- 2.2.1 Genetics -- 2.2.2 Allergies -- 2.2.3 Smoking Tobacco -- 2.2.4 Environmental Factors -- 2.2.5 Obesity -- 2.2.6 Pregnancy -- 2.2.7 The Menstrual Cycle -- 2.2.8 Atopy -- 2.3 Epidemiology/Morbidity (Global Status) -- 2.4 Pathophysiology of Asthma 2.7.2.1 Inhaled Corticosteroids -- 2.7.2.2 Leukotriene Modifiers -- 2.7.2.3 Short-Acting Beta-2 Agonists -- 2.7.2.4 Long-Acting Muscarinic Antagonists (Tiotropium Bromide) -- 2.7.2.5 Short-Acting Muscarinic Antagonists -- 2.7.2.6 IgE-Binding Antibodies -- 2.7.2.7 Mast-Cell Stabilizers (Cromolyn) -- 2.8 Conclusion -- References -- 3: Cystic Fibrosis: Biology and Therapeutics -- 3.1 Introduction -- 3.1.1 About the Disease -- 3.1.2 Epidemiology -- 3.1.3 Causes -- 3.2 Pathophysiology -- 3.2.1 Biology of Disease -- 3.2.1.1 Respiratory System -- 3.2.1.2 Hematopoietic System
• Publisher Details: Singapore : Springer
• Publication Date: 2020
• Extent: 1 online resource (184 p.)
• Subjects: 616.2/4; Lungs -- Diseases; Chronic diseases; Electronic books; Electronic books
• Languages: English
• ISBNs: 9789811537349; 9811537348
• Related ISBNs: 9789811537332
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.